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Methods for the diagnosis of infectious diseases have stagnated in the last 20–30 years. Few major advances in clinical diagnostic
testing have been made since the introduction of PCR, although new technologies are being investigated. Many tests that form the
backbone of the “modern” microbiology laboratory are based on very old and labour-intensive technologies such as microscopy
for malaria. Pressing needs include more rapid tests without sacriﬁcing sensitivity, value-added tests, and point-of-care tests for
bothhigh-andlow-resourcesettings.Inrecentyears,researchhasbeenfocusedonalternativemethodstoimprovethediagnosisof
parasitic diseases. These include immunoassays, molecular-based approaches, and proteomics using mass spectrometry platforms
technology. This review summarizes the progress in new approaches in parasite diagnosis and discusses some of the merits and
disadvantages of these tests.
Copyright © 2009 Momar Ndao. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Currently, the detection and diagnosis of parasite infections
rely on several laboratory methods in addition to clinical
symptoms, clinical history, travel history, and geographic
location of patient. The primary tests currently used to
diagnose many parasitic diseases have changed little since
the development of the microscope in the 15th century
by Antonie van Leeuwenhoek. Furthermore, most of the
current tests cannot distinguish between past, latent, acute,
and reactivated infections and are not useful for following
response to therapy or for prognosis.
Recent developments in new diagnostic tools, however,
have opened new avenues for a vast improvement in parasite
detection. Firstly, a number of newer serology-based assays
that are highly speciﬁc and sensitive have emerged, such
as the Falcon assay screening test ELISA (FAST-ELISA) [1],
Dot-ELISA [2, 3], rapid antigen detection system (RDTS)
[4], and luciferase immunoprecipitation system (LIPS)
[5]. Secondly, molecular-based approaches such as loop-
mediated isothermal ampliﬁcation (LAMP) [6], real-time
p o l y m e r a s ec h a i nr e a c t i o n[ 7], and Luminex [8] have shown
a high potential for use in parasite diagnosis with increased
speciﬁcity and sensitivity. Thirdly, proteomic technology has
also been introduced for the discovery of biomarkers using
tissues or biological ﬂuids from the infected host.
The aim of this review is to highlight the poten-
tial for these new technologies in parasite diagnosis. For
convenience, old and new parasitic diagnostic tools are
summarized in Tables 1 and 2. The diagnostic tools oﬀered
by the CDC (Centre for Disease Control, Atlanta, USA)
and the NRCP (National Reference Centre for Parasitology,
Montr´ eal, Canada) are also highlighted in Tables 3 and 4.
2. Microscopy
For many years, microscopy has been the only tool available
for the detection of parasites through inspection of blood
smears [10–14], tissue specimens [15–17], feces, lymph
node aspirates [18, 19], bone marrow [20], and even cere-
brospinal ﬂuid [21]. However, sample preparation for direct
observation is time-consuming, labour intensive, and proper
diagnosis depends on qualiﬁed laboratory technicians. In
the case of slide reading, a second independent reading is
preferable, but not always required for accurate diagnosis. If
need be, divided readings are resolved by a third reader. In
endemic regions, where resources are limited, this proves to2 Interdisciplinary Perspectives on Infectious Diseases
Table 1: Diagnostic tools for the detection of speciﬁc blood-borne parasitic diseases.
African
trypanosomiasis Babesiosis Chagas
disease Leishmaniasis Malaria Toxoplasmosis
Trypanosoma
brucei
Babesia
microti
Trypanosoma
cruzi
Leishmania
species
Plasmodium
species
Toxoplasma
gondii
MICROSCOPY [23][ 10][ 11][ 12][ 13]—
SEROLOGY-
BASED
ASSAYS
—— — — ——
ELISA [24, 25][ 26][ 27–30]— — [ 31]
FAST-ELISA — — — — [32, 33]—
Dot-ELISA or
Dipstick [34]— [ 35][ 2, 18]— —
RIPA-ELISA — — [36, 37]— — —
DHA or IHA [38]— — [ 18]— —
DFA or IFA [39][ 40, 41]— — [ 42][ 43]
Immunoblot — — [44, 45]— — [ 46]
PRISM — — [47]— — —
RDT — — [48]—[ 49]—
MOLECULAR-
BASED
ASSAYS
—— — — ——
PCR [23][ 50, 51][ 52–54][ 55][ 56][ 57, 58]
RT-PCR [59]— — [ 60–62][ 4, 56][ 63]
QT-NASBA — — — [64][ 65, 66]—
RT-QB-NASBA — — — — [67]—
LAMP [68]— [ 69]— [ 70–74]—
Luminex — — — — [75]—
PCR-ELISA — — — [62, 76][ 77–79]—
OC-PCR [80]— — [ 81]— —
PROTEOMICS — — — — — —
Mass
Spectrometry
(LDMS,
MALDI-TOF,
SELDI-TOF)
[82, 83]— — — [ 84–86]—
FAST-ELISA: Falcon assay screening test; RIPA-ELISA: radioimmunoprecipitation assay; DHA or IHA: direct or indirect hemagglutination assay; DFA or
IFA: direct or indirect immunoﬂuorescence assay; RDT: rapid diagnostic test; LIPS: luciferase immunoprecipitation system; CATT: Card Agglutination test
for Trypanosomiasis; PCR: polymerase chain reaction; RT-PCR: real-time polymerase chain reaction; QT-NASBA: quantitative nucleic acid sequenced-based
ampliﬁcation; RT-QT-NASBA: real-time quantitative nucleic acid sequenced-based ampliﬁcation; LAMP: loop-mediated isothernal ampliﬁcation; OC-PCR:
oligochromatography Polymerase chain reaction; LDMS: laser desorption mass spectrometry; MALDI-ToF: matrix-assisted laser desorption/ionization time
of ﬂight; SELDI-Tof: surface-enhanced laser desorption/ionization time of ﬂight, IFA: immunoﬂuorescent assay, EIA: Enzyme immunoassay, RT-PCR: Real
time PCR, IB: immunoblot.
be diﬃcult and misdiagnosis can signiﬁcantly impact patient
care. In reality, all major intestinal helminth infections
are still solely dependent on microscopy for diagnosis. As
for other parasite infections, many are conﬁrmed by the
use of microscopy in conjunction to other methods of
diagnosis including serology-based assays and more recently
molecular-based assays.
3.Serology-BasedAssays
In situations where biologic samples or tissue specimens are
unavailable,serologyaloneisthegoldstandardfordiagnosis.
Serology-based diagnosis tools can be divided into two
categories: antigen-detection assays and antibody-detection
assays. These include the enzyme-linked immunosorbent
assay (ELISA), also called enzyme immunoassay (EIA), and
all its derived tests such as the Falcon assay screening
test ELISA (FAST-ELISA) and the dot-ELISA. Other assays
include the hemagglutination (HA) test, indirect or direct
immunoﬂuorescent antibody (IFA or DFA) tests, comple-
ment ﬁxation (CF) test, and immunoblotting and rapid
diagnostic tests (RDTs).
Although the ease of use and turnaround times for
serologic assays are similar to microscopy, serology-basedInterdisciplinary Perspectives on Infectious Diseases 3
Table 2: Diagnostic tools for the detection of speciﬁc intestinal parasitic diseases.
PROTOZOA TREMATODES CESTODES NEMATODES
Cryptosporidiosis Fasciolosis Schistosomiasis Taeniasis/
Cysticercosis Hydatidosis Filariasis Strongylodiasis
Cryptosporidium
parvum, C. hominis
Fasciola
hepatica, F.
gigantica
Schistosoma
mansoni Taenia solium
Echinococcus
granulosus, E.
multilocularis
Wuchereria
bancrofti,
Brugia
malayi, B.
timori, Loa
loa
Strongyloides
stercoralis
MICROSCOPY [87][ 88][ 89]— [ 90][ 91][ 92]
SEROLOGY
BASED ASSAYS —— — — — — —
ELISA [93, 94][ 88, 95][ 96, 97][ 98–101][ 102–106][ 14][ 107–111]
FAST-ELISA — [112][ 1]— — — —
Dot-ELISA or
Dipstick —[ 113, 114][ 115]— [ 116, 117][ 118–120]—
DHA or IHA — — [121]— [ 122][ 123][ 124]
DFA or IFA [93, 125, 126]— — — — — [ 127, 128]
Immunoblot — [112][ 129][ 130, 131][ 122]— [ 132]
LIPS — — — — — [133][ 134]
MOLECULAR-
BASED
ASSAYS
—— — — — — —
PCR [135, 136]— [ 137, 138][ 139, 140]— [ 141–143][ 144]
RT-PCR [145–147]— [ 148, 149]— — — [ 150]
LAMP [151, 152]— — [ 153]—— —
Luminex [154]——— — — —
PCR-ELISA — — — — — [155]—
OC-PCR — — [156]—— ——
PROTEOMICS — — — — — — —
Mass
Spectrometry
(LDMS,
MALDI-TOF,
SELDI-TOF)
—[ 157]—[ 158]—— —
Abbreviations: see Table 1.
Table 3: Diagnostic tools for the detection of speciﬁc blood-borne parasitic diseases oﬀered by the CDC and the NRCP.
African
trypanosomiasis Babesiosis Chagas disease Leishmaniasis Malaria Toxoplasmosis
Trypanosoma
brucei species Babesia microti Trypanosoma cruzi Leishmania
species
Plasmodium
species
Toxoplasma
gondii
CDC
DIAGNOSTIC
TOOLS
Microscopy Microscopy IFA,
PCR
Microscopy
culture, IFA, EIA
Microscopy,
Culture, IFA
Microscopy
PCR, IFA
Microscopy IFA,
EIA
NRCP
DIAGNOSTIC
TOOLS
Microscopy,
culture, CATT,
PCR
Microscopy, IFA
Microscopy,
culture, EIA,
RT-PCR
Microscopy,
Culture, IFA,
RT-PCR
Microscopy,
IFA, IB, PCR RT-PCR
CDC: Centre for Disease Control, Atlanta, Georgia, USA. NRCP: National Reference Centre for Parasitology, Montreal General Hospital, Montreal, Quebec,
Canada. Abbreviations: see Table 1.4 Interdisciplinary Perspectives on Infectious Diseases
(a)
(b)
(c)
Figure 1: Microscopy. Comparison of Trypanosoma cruzi trypo-
mastogote (a) with Plasmodium malariae schizont (b) and with
microﬁlaria (c: Mansonella perstans) in squirrel monkey blood
smear. Giemsa stain: 70x oil-immersion objective (a) and (b)
and 27.2x objective (c), adapted with permission of Comparative
Medicine from [9].
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Figure 2: Serology-based assays: ELISA. Enzyme-linked
immunosorbent assay (ELISA) absorbance values for antibodies
to T. cruzi in monkey samples. Median values are indicated by
horizontal lines within the boxes; the 25th and 75th percentiles
are enclosed by the boxes; the 5th and 95th percentiles are
enclosed by the bars outside the boxes. Adapted with permission of
Comparative Medicine from [9].
M12345678
Figure 3: Molecular-based assay: PCR. Example of PCR results
obtained for seven monkey samples, using the TCRUZ primers.
B l o o ds a m p l e sw e r ep r o c e s s e da sd e s c r i b e di nM a t e r i a l sa n d
Methods. The PCR products were electrophoresed in a 2% agarose
gel and stained with ethidium bromide. The 168bp band (arrow)
is the expected T. cruzi-speciﬁc product. The 360 and 550bp are
also speciﬁc products resulting from ampliﬁcation of two or three
ofthe195bprepeatsfoundintandem arraysinthe T. cruzi genome.
Lanes 1 to 6 contain the ampliﬁcation products of DNA from
T. cruzi-infected monkeys; 7, blood from noninfected monkey; 8,
negative control (distilled water); and M, 100bp ladder, adapted,
with permission of Comparative Medicine from [9].
assays are more sensitive and speciﬁc. It becomes important
for individuals whose blood smears do not permit identiﬁ-
cation of the parasite (e.g., diﬀerentiating between Babesia
and Plasmodium)[ 159] or for patients exhibiting low-
parasitemia and/or who are asymptomatic (e.g., Chagasic
patients) [54]. Classifying an infected asymptomatic patient
as negative could lead to transmission of the parasite during
blood transfusions or organ transplants. In the case of
Fasciola infection, serology tests have also been shown to be
useful in the conﬁrmation of chronic fascioliasis when egg
production is low or sporadic [112]. Finally, having these
tests readily available allows for the monitoring of parasite
clearance following therapy.
3.1. Falcon Assay Screening Test ELISA (FAST-ELISA). The
Falcon assay screening test ELISA (FAST-ELISA) consists
of using synthetic and recombinant peptides to evaluate
antibody responses to an antigen [1]. In the past, the method
has been applied to the study of malaria [32], fasciolosis
[112], schistosomiasis (reviewed in [160]), and taeniasis
[161]. However, this technique is subjected to the same
drawbacks as most serology-based tests. Antibodies raised
against a peptide from one parasite protein may cross-react
withproteinsfromotherspecies.Moreover,antibodiesraised
against a peptide may react in some assays but not in others
and some regions of a peptide may be more immunogenic
thanothers.Norecentstudieshavebeenpublishedontheuse
of the FAST-ELISA for the diagnosis of parasitic infections.Interdisciplinary Perspectives on Infectious Diseases 5
Table 4: Diagnostic tools for the detection of speciﬁc intestinal parasitic diseases oﬀered by the CDC and the NRCP.
PROTOZOA TREMATODES CESTODES NEMATODES
Cryptosporidiosis Fasciolosis Schistosomiasis Taeniasis
Cysticercosis Hydatidosis Filariasis Strongylodiasis
Cryptosporidium
parvum, C. hominis
Fasciola
hepatica, F.
gigantica
Schistosoma
mansoni Taenia solium
Echinococcus
granulosus, E.
multilocularis
Wuchereria
bancrofti,
Brugia
malayi, B.
timori, Loa
loa
Strongyloides
stercoralis
CDC DIAG-
NOSTIC
TOOLS
Microscopy, EIA,
PCR, RT-PCR — Microsocopy,
FAST-ELISA, IB Immunoblot, IB Microscopy,
EIA Microscopy, EIA
NRCP DIAG-
NOSTIC
TOOLS
Microscopy, EIA Microscopy,
EIA Microscopy, EIA IB EIA Microscopy,
EIA
Microscopy,
culture, EIA, IB
CDC: Centre for Disease Control, Atlanta, Georgia, USA. NRCP: National Reference Centre for Parasitology, Montreal General Hospital, Montreal, Quebec,
Canada.
3.2. Dot-ELISA. The main diﬀerence between the regular
ELISA and the dot-ELISA lies in the surface used to bind
the antigen of choice. In the dot-ELISA, the plastic plate is
replaced by a nitrocellulose or other paper membrane onto
which a small amount of sample volume is applied. The
choice of binding matrix greatly improved the speciﬁcity and
sensitivityoftheassaybyreducingthebinding ofnonspeciﬁc
proteins usually observed when plastic binding matrixes
are used. The principle is similar to the immunoblot. The
dotted membrane is incubated ﬁrst with an antigen-speciﬁc
antibody followed by an enzyme-conjugated anti-antibody.
The addition of a precipitable, chromogenic substrate causes
the formation of a colored dot on the membrane which can
be visually read [2]. The beneﬁts of this technique include its
ease of use, its rapidity, and the ease of result interpretation.
Itisfast,andcost-eﬀectiveandmoreimportantlycanbeused
in the ﬁeld (e.g., as a dipstick). For all these reasons, the Dot-
ELISA has been and still is extensively used in the detection
of human and animal parasitic diseases, including amebiasis,
babesiosis, fascioliasis, cutaneous and visceral leishmania-
sis, cysticercosis, echinococcosis, malaria, schistosomiasis,
toxocariasis, toxoplasmosis, trichinosis, and trypanosomiasis
(all reviewed in [3]). In the last few years, published
studies have demonstrated the use of the dot-ELISA for the
detection of Fasciola gigantica [113], Haemonchus contortus
[162], Theileria equi [163], Trypanosoma cruzi [164], and
Trypanosoma brucei [34]. In the latter study the researchers
were able to demonstrate that the dot-ELISA had better
sensitivity and speciﬁcity than the ELISA in the detection
of antineuroﬁlament and antigalactocerebrosides antibodies
in cerebrospinal ﬂuid of subjects infected with African
trypanosomes. They attributed the greater sensitivity and
speciﬁcity of the dot-ELISA to the use of the nitrocellulose
membrane and showed that their assay was successfully
reproducible in the ﬁeld.
3.3. Rapid Antigen Detection System (RDTS). Rapid antigen
detection tests (RDTs) based on immunochromatographic
antigen detection have been implemented in many diagnos-
tic laboratories as an adjunct to microscopy for the diagnosis
of malaria. RDTs consist of capturing soluble proteins by
complexing them with capture antibodies embedded on a
nitrocellulose strip. A drop of blood sample is applied to the
strip and eluted from the nitrocellulose strip by the addition
of a few drops of buﬀer containing a labeled antibody. The
antigen-antibody complex can then be visualized directly
from the membrane [4].
Since the appearance of the ﬁrst RDTs in the 990s, major
improvements have been made to the technique, making the
use of RDTs in rural endemic regions feasible. RDTs are
now rapid, stable at temperatures up to 40◦C, easy to use,
and cost-eﬀective thereby providing many advantages over
traditional microscopic methods [165]. RDTs are useful in
the identiﬁcation of P. falciparum and P. vivax infections but
cannot be used to identify P. malariae and P. ovale infections
[4].Inaddition,theyareuselessatdetectingverylow-density
infections. PCR-based approaches remain the tool of choice
inthatsituation.Morethan80RDTsexistforthedetectionof
either histidine-rich protein (HRP) speciﬁc to P. falciparum
or species-speciﬁc isotypes of lactate dehydrogenase (LDH)
[49]. However, as reported by Murray et al. [165]o n l y2 3
have met the WHO’s criteria for international marketing.
Malaria RDTs have recently been introduced in African
countries to help prevent misdiagnosis of malaria infections
and to subsequently reduce the practice of presumptive
treatment [49]. In fact, the tendency to treat slide-negative
samples with antimalarials is still a common phenomenon.
This practice causes concern not only for the patient’s
health care but also to the costs it generates in prescribing
the more expensive antimalarial sulfadoxine/pyrimethamine
and artemisinin-based combinations [165]. Finally, misuse
of antimalarials could lead to the appearance of drug-
resistant strains.6 Interdisciplinary Perspectives on Infectious Diseases
3.4. Luciferase Immunoprecipitation System (LIPS). The
luciferase immunoprecipitation system (LIPS) is a modiﬁed
ELISA-based assay in which serum containing antigen-
speciﬁc antibodies can be identiﬁed by measuring light
production. Basically, an antigen of choice is fused to the
enzyme reporter Renilla luciferase (Ruc) and expressed as
a Ruc-fusion in mammalian cells to allow for mammalian-
speciﬁc posttranslational modiﬁcations. The crude protein
extract is then incubated with the test serum and protein
A/G beads. During the incubation, the Ruc-antigen fusion
becomes immobilized on the A/G beads, which allows the
antigen-speciﬁc antibody to be quantitated by washing the
beads and adding coelenterazine substrate and measuring
light production [5].
In recent years, LIPS has been successfully applied for
the identiﬁcation of sera samples infected with Strongyloides
stercoralis (using a Ruc-NIE fusion) [134]a n dLoa loa (using
a Ruc-LlSXP-1 fusion) [133]. Some of the advantages of
the LIPS technology include its rapidity and accuracy in
detecting infected patients. Sensitivity is improved in part by
the use of mammalian cells which produce fusion antigens
free of contaminating bacterial proteins. In addition, low
backgrounds are produced compared to the ELISA. This
greatly facilitates the separation between negative and pos-
itive samples. In addition, the Strongyloides LIPS based on
the NIE antigen showed greater speciﬁcity than the ELISA
as no cross-reaction was observed with serum from ﬁlarial-
infected subjects [134].
A LIPS assay can be performed in 2.5 hours. Burbelo
et al. 2008 [133] were able to obtain 100% speciﬁcity and
sensitivity when performing an LIPS assay based on the
Loa loa SXP-1 antigen with only a small-degree of cross-
reactivity with a few Onchocerca volvulus-a n dWuchereria
bancrofti-infected patient sera. By decreasing the incubation
times of a normal LIPS assay, they were able to minimize
cross-reaction. Many of the O. volvulus sera samples tested
as positive with the LIPS assay were negative using this 15-
minute LIPS assay also called QLIPS. Of interest for the
application of this technique in the ﬁeld is the observation
that blood obtained by ﬁnger-prick (contaminated with red
blood cells and other components) did not interfere with the
LIPS assay. Further studies will be useful in exploring and
validating the accuracy and potential usefulness of the LIPS
and QLIPS assays in the ﬁeld.
As discussed, immunodiagnostics tests have some
serious limitations. Parasitic diseases such as amebiasis,
cryptosporidiosis, ﬁlariasis, giardiasis, malaria, cysticercosis,
schistosomiasis, and African trypanosomiasis do not have
commercially or FDA approved antibody detection tests
for their diagnosis. Experimental results have been too
variable due to the type of antigen preparations used (e.g.,
crude, recombinant puriﬁed, adult worm, egg) and also
because of the use of nonstandardized test procedures.
Cross-reaction leading to false-positives and misdiagnosis is
also a problem, especially in regions where more than one
parasite is endemic. Despite the fact that some parasites in
South America share common epitopes, it is common to see
coinfection with Trypanosoma cruzi and Leishmania species
[166]. It is also a problem in Africa, where cross-reactivity
exists between ﬁlarial and other helminth antigens [133]. To
a lesser extent but nonetheless important is the inability of
antibody-detection tests to diﬀerentiate between past and
currently active infections [167]. Furthermore, antibody-
detection tests cannot be used in parasitic infections
that do not develop a signiﬁcant antibody response.
This has been observed in some individuals carrying
Echinococcus cysts [168] or during cutaneous leishmaniasis
(http://www.dpd.cdc.gov/dpdx/HTML/Leishmaniasis.htm).
Similarly, in the case of African trypanosomiasis diagnosis,
such tests are of limited use because seroconversion occurs
only after the onset of clinical symptoms [83].
For all these reasons, there is still a need to improve on
the current diagnosis approaches available. Since the advent
of the polymerase chain reaction (PCR), parasitologists have
turned to molecular-based approaches in the hopes to better
the existing diagnosis tools.
4.Molecular-BasedApproaches
4.1. Nucleic Acid-Based Approaches. The many limitations
of microscopy and serology-based assays have inﬂuenced
parasitologists towards the use of gene ampliﬁcation meth-
ods made possible with the advent of the polymerase
chain reaction (PCR). Besides the traditional PCR, including
nested and multiplexed PCR, we have seen the implemen-
tation of the real-time PCR (RT-PCR) for the detection
of several parasitic infections. Newer technologies such as
loop-mediated isothermal ampliﬁcation and Luminex-based
assays have also emerged as possible new approaches for the
diagnosis of parasitic diseases.
Molecular-based approaches based on nucleic acids oﬀer
greater sensitivity and speciﬁcity over the existing diagnostic
tests. They permit the detection of infections from very
low parasitized samples including those from asymptomatic
patient’s samples [169]. Moreover, multiplexed PCR allows
for the detection of multiple sequences in the same reaction
tube proving useful in the diagnosis of several parasitic
infections simultaneously [170].
4.2. Real-Time Polymerase Chain Reaction (RT-PCR). RT-
PCR system unlike conventional PCR, allow for the quantiﬁ-
cation of the original template’s concentration through the
use of various ﬂuorescent chemistries, such as Sybergreen,
Taqman probes, ﬂuorescence resonance energy transfer
(FRET), and Scorpion primers [7]. The concentration is
measured through comparison to standard curves. This
eliminates the need to visualize the amplicons by gel
electrophoresis thereby greatly reducing the risk of contam-
ination and the introduction of false-positives. When mul-
tiplexed, RT-PCR allows for the high-throughput analysis of
diﬀerent sequences in one single-closed tube reaction [171].
Using multiplexed RT-PCR, Shokoples et al. [4]w e r ea b l e
to identify the four human Plasmodium species (falciparum,
vivax, malariae,a n dovale) in a single reaction tube even in
very low parasitized samples. Running the multiplex assay
not only reduced the cost per test but also allowed for a
rapid turnaround time, the assay taking only three hours toInterdisciplinary Perspectives on Infectious Diseases 7
complete. It is a clear advantage over microscopy which is
labour intensive and time-consuming with slow turnaround
times especially during high-throughput settings. Similarly,
multiplexed RT-PCR proved useful in diﬀerentiating drug-
sensitive strains of malaria [172]. This is important for
proper antimalarial prescription. In another example, Diez
et al. [54]w e r ea b l et od e t e c tt h ep r e s e n c eo fT. cruzi infec-
tion following heart transplants using PCR. This allowed
immediate treatment of the patients before reactivation of
Chagas disease could occur. These examples demonstrate
that eﬃcient and early diagnosis can directly impact patients
care and that PCR-based approaches have the potential to
help in making the right choice for treatment.
Although DNA-based methods have shown excellent
sensitivity and speciﬁcity, the introduction of these methods
in daily laboratory practice is still uncommon especially in
rural endemic regions. In addition, as observed with many
serology-based assays, PCR-based methods also suﬀer by
the lack of standardization [22]. DNA extraction, choice of
primer sets, and use of various ampliﬁcation protocols are
all factors that may cause this diversiﬁcation in results [173].
Adding an automated DNA extraction step would certainly
improve PCR assays for use in the diagnosis of parasitic
diseases.
4.3. Loop-Mediated Isothermal Ampliﬁcation (LAMP). Loop-
mediated isothermal ampliﬁcation (LAMP) is a unique
ampliﬁcation method with extremely high speciﬁcity and
sensitivity able to discriminate between a single nucleotide
diﬀerence [6]. It is characterised by the use of six diﬀerent
primers speciﬁcally designed to recognise eight distinct
regions on a target gene, with ampliﬁcation only occurring if
allprimersbindandformaproduct[174].Inthepast,LAMP
has been successfully applied for the rapid detection of both
DNA and RNA viruses such as the West Nile [175]a n d
SARS viruses [176]. Recently, parasitologists have adapted
the LAMP approach for the detection of several parasitic
diseases including the human parasites Entamoeba [177],
Trypanosoma [68], Taenia [153], Plasmodium [70], and
Cryptosporidium [152], the animal parasites Theilera [178]
and Babesia [178, 179], and even to the identiﬁcation of
vector mosquitoes carrying Plasmodium [73]a n dDiroﬁlaria
immitis[180]parasites.Mostofthesestudieshavebroughtto
light the many advantages of this method over the common
PCR technique.
Unlike a regular PCR reaction, LAMP is carried out at
a constant temperature (usually in the range of 60–65◦C).
This unique feature not only results in higher yields, but also
eliminates the need to buy a thermal cycler and shortens
the reaction time by eliminating time lost during thermal
changes. In addition, the reaction can be carried out without
extracting the DNA from the collected samples as shown in
the case of RIME, a nonautonomous retroelement found in
Trypanosoma brucei rhodesiense and T. b. gambiense [68]. In
35 minutes, using a simple water bath, RIME LAMP was able
to detect both T. b. gambiense and T. b. rhodesiense directly
from blood, serum, and CSF samples. More importantly, the
study has shown reproducibility in the ﬁeld. In addition to
the above advantages, LAMP reactions are easy to set up,
and results can readily be assessed. The sample of interest
is mixed with primers, substrates, and a DNA polymerase
capable of strand displacement in a microcentrifuge tube.
During the reaction, large amounts of pyrophosphate ions
are produced, leading to the formation of a white precipitate
[181]. This turbidity is proportional with the amount of
DNA synthesized therefore one can assess the reaction by
real-time measurement of turbidity or more importantly,
simply through the naked-eye.
For all these reasons, the future adoption of LAMP as
a diagnostic tool for parasite infections in rural endemic
regions shows promise. Furthermore, as more groups apply
LAMP to the ﬁeld of parasitology, we will see the appear-
ance of LAMP-modiﬁed assays that meet speciﬁc detection
needs. For example, in a recent study on bovine Babesia
[182], a multiplex-LAMP (mLAMP) assay was developed to
simultaneously detect B. bovis and B. bigemina from DNA
extracted from blood spotted on ﬁlter paper. Similarly, Han
etal.[71]implementedaLAMPassaybasedonthe18SrRNA
geneforthedetectionofthefourhumanPlasmodiumspecies
(falciparum, vivax, malariae,a n dovale). LAMP had a similar
sensitivity and a greater speciﬁcity than nested PCR, yielding
similar results but at a faster turnaround time. Their results
are consistent with other studies demonstrating the rapidity
and the improved speciﬁcity and sensitivity obtained using
the LAMP assay.
4.4. Luminex xMAP Technology. Luminex technology
is a bead-based ﬂow-cytometric assay that allows
the detection of various targets simultaneously
(http://www.luminexcorp.com/). The microsphere beads
can be covalently bound to antigens, antibodies, or oligonu-
cleotides that will serve as probes in the assay. Up to 100
microspheres are available each emitting unique ﬂuorescent
signals when excited by laser therefore allowing the identiﬁ-
cation of diﬀerent targets [183]. Adapted to the study of par-
asites, the Luminex assay could identify multiple organisms
or diﬀerent genotypes of one particular organism during the
samereactionutilizing verylowvolume.Theapproachcould
prove useful in the study of antigenic diversity and drug-
resistance alleles and for the diagnosis of parasitic diseases.
Luminex was applied to the study of Cryptosporidium
[154]. C. hominis and C. parvum cannot be distinguished
using antigen detection or serology assays. Only DNA-based
approaches have been successful in doing so by exploiting
the single nucleotide diﬀerence in the microsatellite-2 region
(ML-2) of both species [154]. Ultimately DNA sequencing is
the diagnosis tool of choice but it is costly, labour-intensive
and time-consuming. In a recent study, Bandyopadhyay
et al. [154] successfully detected and distinguished C.
hominis and C. parvum in 143 DNA extracts using Luminex
technology by using oligonucleotide probes speciﬁc to the
ML-2 regions of each species. Turnaround time was about
5 hours making this assay not only much faster but also
less expensive than PCR followed by DNA sequencing. It
also proved to be 100% speciﬁc and more sensitive than a
direct ﬂuorescent antibody (DFA) test, a method routinely8 Interdisciplinary Perspectives on Infectious Diseases
used to identify Cryptosporidium and Giardia species. Note
that DFA cannot diﬀerentiate between C. hominis and C.
parvum.
Similarly in other research, Luminex technology was
able to detect all-blood stage parasite levels of the four
humanPlasmodiumspecies(falciparum,vivax,malariae,and
ovale) simultaneously [75]. This study demonstrated that
Luminex technology can improve the speed, the accuracy,
and the reliability of other PCR methods. For example,
the need for gel electrophoresis to diﬀerentiate the LDR
products representing the four human Plasmodium species
iseliminated.Second,allsamplesarehandledsimultaneously
and continuously through a 96-well plate format from DNA
extraction all through data analysis. The process is auto-
mated and therefore uniformity can be achieved. Finally, the
high-throughput capability of the Luminex system confers it
aclearadvantageovertheuseoflabour-intensivemicroscopy
for large scale studies.
4.5. Proteomics. Since proteins are the main catalysts,
structural elements, signalling messengers, and molecular
machines of biological tissues, proteomic studies are able
to provide substantial clinical relevance. Proteins can be
utilized as biomarkers for tissues, cell types, developmental
stages, and disease states as well as potential targets for
drug discovery and interventional approaches. The next
generation of diagnostic tests for infectious diseases will
emerge from proteomic studies of serum and other body
ﬂuids. Recent advances in this area are attributable largely
to the introduction of mass spectrometry platforms capa-
ble of screening complex biological ﬂuids for individual
protein and peptide “biomarkers.” Proteomic strategy can
identify proteins in two ways: bottom-up and top-down
approaches. In the former, the proteins in a biological ﬂuid
are proteolytically shattered into small fragments that can be
easily sequenced and the resultant spectra are compared with
those in established peptide databases. This is the protein
equivalent of “shotgun” genomics. Bottom-up strategies
are diﬃcult to quantitate and cannot identify modiﬁed
molecules (e.g., alternately spliced, glycosylated). Since each
open reading frame in the human genome is thought to
generate at least 10 modiﬁed proteins, this issue is a major
limitation.
The classic top-down strategy is 2-dimensional gel
electrophoresis.Top-downstrategiesseektoidentifyproteins
and peptides (and their natural variants) in complex biologi-
calﬂuids. Two-dimensional(2D)gelelectrophoresiswasﬁrst
described in 1975. With this method, proteins are resolved in
the ﬁrst dimension based on pH (a process called isoelectric
focusing) and in the second dimension by their molecular
weight.Thistechniqueislaborintensive,andlowthroughput
and requires large amounts of sample. Such limitations
have encouraged the search for improved approaches. Other
techniques used for the expression analysis of proteins are
matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS), surface-enhanced
laser desorption ionization time of ﬂight mass spectrom-
etry (SELDI-TOF MS), liquid chromatography combined
with MS (LC–MS–MS), isotope-coded aﬃnity tags (ICAT),
and isotope tags for relative and absolute quantiﬁcation
(iTRAQ).
The development of automated, high-throughput pro-
teomic technologies such as MALDI-TOF and SELDI-TOF
MS has enabled large numbers of clinical samples to be
analyzed simultaneously in a short time. These platforms
have made “population-based proteomics” feasible for the
ﬁrst time (reviewed in [184]). All proteomics-based diag-
nostic eﬀorts seek to identify biomarkers that, alone or in
combination, can distinguish between “case” and “control”
groups.
The main limitation of SELDI compared to MALDI
resides in the fact that SELDI has lower resolution and lower
mass accuracy. In addition, SELDI is unsuitable for high
molecular weight proteins (>100kDa) and is limited to the
detection of bound proteins on to the ProteinChip Array.
Most studies published about parasitic diseases have
focused on SELDI. The SELDI, a derivation of MALDI,
allows sample binding to chemically active ProteinChip sur-
faces. Several types of ProteinChip arrays are available with
diﬀering abilities to bind proteins with diﬀerent chemical
(anionic, cationic, hydrophobic, metallic, and normal phase)
or biological (antibody, enzymes, receptors) properties,
therebyallowingthedirectanalysisofproteinsfromcomplex
biological samples without the need for prior separation
by 2D gel electrophoresis. The output of the SELDI is a
spectrum of mass-to-charge ratios (m:z values) with their
corresponding relative intensities (approximating to relative
abundance).
SELDI analyses were initially applied to the discovery
of early diagnostic or prognostic biomarkers of cancer
(reviewedin[185]).Recently,thistechniquehasbeenapplied
to the study of serum biomarkers of infectious diseases
such as Severe Acute Respiratory Syndrome [186], African
trypanosomiasis [83], fascioliasis [157], cysticercosis [158],
and Chagas diseases (Ndao et al., submitted). Such studies
have focused on identifying a distinctive conﬁguration of
circulating serum proteins that are indicative of a speciﬁc
pathophysiological state, a so-called “proteomic ﬁngerprint.”
The real potential of proteomic ﬁngerprinting is in
its use as a discovery tool for novel biomarkers that can
then be incorporated into simple bedside diagnostics based
on aﬀordable technologies such as immunologically based
antigen-detectionteststhatcouldbeimplementedindipstick
or cassette formats.
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